Cassava Sciences, Inc. Logo

Cassava Sciences, Inc.

SAVA

(0.5)
Stock Price

26,91 USD

-6.31% ROA

-10.98% ROE

-78.3x PER

Market Cap.

1.249.780.010,00 USD

0% DER

0% Yield

-654.68% NPM

Cassava Sciences, Inc. Stock Analysis

Cassava Sciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cassava Sciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

Negative ROE (-41.76%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-42.93%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.24x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Cassava Sciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cassava Sciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Cassava Sciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cassava Sciences, Inc. Revenue
Year Revenue Growth
1999 1
2000 1 0%
2001 0 0%
2002 114.000 100%
2003 0 0%
2004 0 0%
2005 5.080.000 100%
2006 53.918.000 90.58%
2007 65.984.000 18.29%
2008 63.725.000 -3.54%
2009 20.563.000 -209.9%
2010 16.809.000 -22.33%
2011 11.484.000 -46.37%
2012 10.890.000 -5.45%
2013 41.119.000 73.52%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 -1.800 100%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cassava Sciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 2.092.119
2000 12.596.169 83.39%
2001 11.667.689 -7.96%
2002 11.396.000 -2.38%
2003 18.913.000 39.75%
2004 35.093.000 46.11%
2005 32.938.000 -6.54%
2006 46.803.000 29.62%
2007 47.730.000 1.94%
2008 45.817.000 -4.18%
2009 21.059.000 -117.56%
2010 15.746.000 -33.74%
2011 8.300.000 -89.71%
2012 7.605.000 -9.14%
2013 4.917.000 -54.67%
2014 7.306.000 32.7%
2015 9.100.000 19.71%
2016 9.176.000 0.83%
2017 7.615.000 -20.5%
2018 2.969.000 -156.48%
2019 1.568.000 -89.35%
2020 3.053.000 48.64%
2021 24.813.000 87.7%
2022 68.032.000 63.53%
2023 94.412.000 27.94%
2023 89.423.000 -5.58%
2024 60.792.000 -47.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cassava Sciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 7.708.740 100%
2001 5.647.021 -36.51%
2002 0 0%
2003 3.338.000 100%
2004 3.868.000 13.7%
2005 4.859.000 20.4%
2006 7.668.000 36.63%
2007 8.085.000 5.16%
2008 9.196.000 12.08%
2009 6.258.000 -46.95%
2010 14.766.000 57.62%
2011 6.698.000 -120.45%
2012 7.182.000 6.74%
2013 4.837.000 -48.48%
2014 5.127.000 5.66%
2015 5.102.000 -0.49%
2016 5.781.000 11.75%
2017 4.334.000 -33.39%
2018 3.693.000 -17.36%
2019 3.391.000 -8.91%
2020 3.739.000 9.31%
2021 8.055.000 53.58%
2022 11.988.000 32.81%
2023 17.104.000 29.91%
2023 16.534.000 -3.45%
2024 184.816.000 91.05%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cassava Sciences, Inc. EBITDA
Year EBITDA Growth
1999 -3.120.382
2000 -14.146.709 77.94%
2001 -15.871.377 10.87%
2002 17.268.000 191.91%
2003 -21.910.000 178.81%
2004 -38.578.000 43.21%
2005 -32.349.000 -19.26%
2006 -553.000 -5749.73%
2007 10.525.000 105.25%
2008 9.164.000 -14.85%
2009 -6.754.000 235.68%
2010 -13.471.000 49.86%
2011 -3.514.000 -283.35%
2012 -3.897.000 9.83%
2013 31.365.000 112.42%
2014 -12.433.000 352.27%
2015 -14.202.000 12.46%
2016 -14.957.000 5.05%
2017 -11.949.000 -25.17%
2018 -6.662.000 -79.36%
2019 -4.959.000 -34.34%
2020 -7.138.000 30.53%
2021 -32.868.000 78.28%
2022 -80.020.000 58.93%
2023 -111.516.000 28.24%
2023 -104.427.000 -6.79%
2024 -267.608.000 60.98%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cassava Sciences, Inc. Gross Profit
Year Gross Profit Growth
1999 1.539.092
2000 6.158.200 75.01%
2001 0 0%
2002 114.000 100%
2003 0 0%
2004 0 0%
2005 5.080.000 100%
2006 53.918.000 90.58%
2007 65.984.000 18.29%
2008 63.725.000 -3.54%
2009 20.563.000 -209.9%
2010 16.809.000 -22.33%
2011 11.484.000 -46.37%
2012 10.882.395 -5.53%
2013 41.114.083 73.53%
2014 -7.306 562844.09%
2015 -45.000 83.76%
2016 -58.000 22.41%
2017 -68.000 14.71%
2018 -69.000 1.45%
2019 -58.000 -18.97%
2020 -346.000 83.24%
2021 -534.000 35.21%
2022 -1.302.800 59.01%
2023 0 0%
2023 -89.423.000 100%
2024 -1.200.000 -7351.92%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cassava Sciences, Inc. Net Profit
Year Net Profit Growth
1999 -4.499.585
2000 -17.479.790 74.26%
2001 -14.337.350 -21.92%
2002 -15.925.000 9.97%
2003 -21.617.000 26.33%
2004 -37.776.000 42.78%
2005 -30.670.000 -23.17%
2006 6.188.000 595.64%
2007 20.305.000 69.52%
2008 15.347.000 -32.31%
2009 -3.467.000 542.66%
2010 -12.023.000 71.16%
2011 -2.613.000 -360.12%
2012 -3.446.000 24.17%
2013 31.544.000 110.92%
2014 -12.386.000 354.67%
2015 -14.145.000 12.44%
2016 -14.850.000 4.75%
2017 -11.911.000 -24.67%
2018 -6.557.000 -81.65%
2019 -4.245.000 -54.46%
2020 -5.854.000 27.49%
2021 -31.802.000 81.59%
2022 -72.472.000 56.12%
2023 -102.604.000 29.37%
2023 -97.217.000 -5.54%
2024 24.620.000 494.87%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cassava Sciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 -9
2000 -9 -12.5%
2001 -4 -166.67%
2002 -4 25%
2003 -5 20%
2004 -7 28.57%
2005 -5 -75%
2006 1 0%
2007 3 100%
2008 3 -50%
2009 -1 0%
2010 -2 100%
2011 0 0%
2012 -1 0%
2013 5 100%
2014 -2 500%
2015 -2 50%
2016 -2 0%
2017 -2 -100%
2018 -1 0%
2019 0 0%
2020 0 0%
2021 -1 0%
2022 -2 100%
2023 -2 50%
2023 -2 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cassava Sciences, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -2.732.846
2000 -8.687.445 68.54%
2001 -13.713.187 36.65%
2002 -15.505.000 11.56%
2003 -20.533.000 24.49%
2004 -32.725.000 37.26%
2005 112.769.000 129.02%
2006 -11.921.000 1045.97%
2007 1.535.000 876.61%
2008 9.041.000 83.02%
2009 -14.691.000 161.54%
2010 -143.000 -10173.43%
2011 -260.000 45%
2012 -7.171.000 96.37%
2013 -6.947.000 -3.22%
2014 -9.629.000 27.85%
2015 -9.248.000 -4.12%
2016 -12.309.000 24.87%
2017 -8.237.000 -49.44%
2018 -4.770.000 -72.68%
2019 -2.532.000 -88.39%
2020 -5.382.000 52.95%
2021 -52.410.000 89.73%
2022 -80.226.000 34.67%
2023 -26.552.000 -202.15%
2023 -82.439.000 67.79%
2024 -18.270.000 -351.23%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cassava Sciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -2.694.301
2000 -7.385.315 63.52%
2001 -12.371.258 40.3%
2002 -15.498.000 20.18%
2003 -20.507.000 24.43%
2004 -32.569.000 37.04%
2005 113.232.000 128.76%
2006 -11.827.000 1057.4%
2007 2.231.000 630.12%
2008 11.163.000 80.01%
2009 -14.691.000 175.99%
2010 -143.000 -10173.43%
2011 -260.000 45%
2012 -7.171.000 96.37%
2013 -6.947.000 -3.22%
2014 -9.549.000 27.25%
2015 -9.053.000 -5.48%
2016 -12.234.000 26%
2017 -8.237.000 -48.52%
2018 -4.770.000 -72.68%
2019 -2.514.000 -89.74%
2020 -5.382.000 53.29%
2021 -30.196.000 82.18%
2022 -77.514.000 61.04%
2023 -26.530.000 -192.17%
2023 -82.025.000 67.66%
2024 -18.241.000 -349.67%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cassava Sciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 38.545
2000 1.302.130 97.04%
2001 1.341.929 2.97%
2002 7.000 -19070.41%
2003 26.000 73.08%
2004 156.000 83.33%
2005 463.000 66.31%
2006 94.000 -392.55%
2007 696.000 86.49%
2008 2.122.000 67.2%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 80.000 100%
2015 195.000 58.97%
2016 75.000 -160%
2017 0 0%
2018 0 0%
2019 18.000 100%
2020 0 0%
2021 22.214.000 100%
2022 2.712.000 -719.1%
2023 22.000 -12227.27%
2023 414.000 94.69%
2024 29.000 -1327.59%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cassava Sciences, Inc. Equity
Year Equity Growth
1999 9.140.586
2000 78.694.668 88.38%
2001 65.616.325 -19.93%
2002 50.224.000 -30.65%
2003 76.562.000 34.4%
2004 93.396.000 18.02%
2005 63.360.000 -47.41%
2006 77.915.000 18.68%
2007 103.914.000 25.02%
2008 104.286.000 0.36%
2009 108.252.000 3.66%
2010 32.933.000 -228.7%
2011 44.393.000 25.81%
2012 13.136.000 -237.95%
2013 48.302.000 72.8%
2014 40.056.000 -20.59%
2015 29.367.000 -36.4%
2016 18.637.000 -57.57%
2017 9.699.000 -92.15%
2018 19.628.000 50.59%
2019 22.099.000 11.18%
2020 92.200.000 76.03%
2021 253.915.000 63.69%
2022 227.539.000 -11.59%
2023 155.115.000 -46.69%
2023 137.468.000 -12.84%
2024 188.974.000 27.26%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cassava Sciences, Inc. Assets
Year Assets Growth
1999 9.441.173
2000 81.147.046 88.37%
2001 68.135.796 -19.1%
2002 53.325.000 -27.77%
2003 80.513.000 33.77%
2004 101.192.000 20.44%
2005 215.795.000 53.11%
2006 208.456.000 -3.52%
2007 207.625.000 -0.4%
2008 193.436.000 -7.34%
2009 182.005.000 -6.28%
2010 99.195.000 -83.48%
2011 98.963.000 -0.23%
2012 56.859.000 -74.05%
2013 50.103.000 -13.48%
2014 40.906.000 -22.48%
2015 31.918.000 -28.16%
2016 19.302.000 -65.36%
2017 10.831.000 -78.21%
2018 20.139.000 46.22%
2019 23.486.000 14.25%
2020 94.300.000 75.09%
2021 266.782.000 64.65%
2022 234.834.000 -13.6%
2023 172.529.000 -36.11%
2023 151.663.000 -13.76%
2024 243.568.000 37.73%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cassava Sciences, Inc. Liabilities
Year Liabilities Growth
1999 300.587
2000 2.452.378 87.74%
2001 2.519.471 2.66%
2002 3.101.000 18.75%
2003 3.951.000 21.51%
2004 7.796.000 49.32%
2005 152.435.000 94.89%
2006 130.541.000 -16.77%
2007 103.711.000 -25.87%
2008 89.150.000 -16.33%
2009 73.753.000 -20.88%
2010 66.262.000 -11.31%
2011 54.570.000 -21.43%
2012 43.723.000 -24.81%
2013 1.801.000 -2327.71%
2014 850.000 -111.88%
2015 2.551.000 66.68%
2016 665.000 -283.61%
2017 1.132.000 41.25%
2018 511.000 -121.53%
2019 1.387.000 63.16%
2020 2.100.000 33.95%
2021 12.867.000 83.68%
2022 7.295.000 -76.38%
2023 17.414.000 58.11%
2023 14.195.000 -22.68%
2024 54.594.000 74%

Cassava Sciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.05
Net Income per Share
-0.33
Price to Earning Ratio
-78.3x
Price To Sales Ratio
532.27x
POCF Ratio
-13.96
PFCF Ratio
-14.48
Price to Book Ratio
6.37
EV to Sales
443.99
EV Over EBITDA
-7.62
EV to Operating CashFlow
-12.09
EV to FreeCashFlow
-12.08
Earnings Yield
-0.01
FreeCashFlow Yield
-0.07
Market Cap
1,25 Bil.
Enterprise Value
1,04 Bil.
Graham Number
5.53
Graham NetNet
3.33

Income Statement Metrics

Net Income per Share
-0.33
Income Quality
5.61
ROE
-0.11
Return On Assets
-0.06
Return On Capital Employed
-0.73
Net Income per EBT
1
EBT Per Ebit
0.11
Ebit per Revenue
-58.69
Effective Tax Rate
-0.36

Margins

Sales, General, & Administrative to Revenue
24.8
Research & Developement to Revenue
31.42
Stock Based Compensation to Revenue
3.41
Gross Profit Margin
0.42
Operating Profit Margin
-58.69
Pretax Profit Margin
-6.55
Net Profit Margin
-6.55

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.87
Free CashFlow per Share
-1.87
Capex to Operating CashFlow
-0
Capex to Revenue
0.04
Capex to Depreciation
0.07
Return on Invested Capital
-0.99
Return on Tangible Assets
-0.06
Days Sales Outstanding
223.66
Days Payables Outstanding
14114.41
Days of Inventory on Hand
0
Receivables Turnover
1.63
Payables Turnover
0.03
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
4,49
Book Value per Share
4,09
Tangible Book Value per Share
4.09
Shareholders Equity per Share
4.09
Interest Debt per Share
0.06
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.51
Current Ratio
4.07
Tangible Asset Value
0,19 Bil.
Net Current Asset Value
0,17 Bil.
Invested Capital
188974000
Working Capital
0,17 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,03 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cassava Sciences, Inc. Dividends
Year Dividends Growth
2010 2
2012 1 0%

Cassava Sciences, Inc. Profile

About Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

CEO
Mr. Richard Jon Barry
Employee
29
Address
7801 North Capital of Texas Highway
Austin, 78731

Cassava Sciences, Inc. Executives & BODs

Cassava Sciences, Inc. Executives & BODs
# Name Age
1 Mr. Richard Jon Barry
Chief Executive Officer & Director
70
2 Dr. James W. Kupiec M.D.
Chief Medical Officer
70
3 Mr. Michael Zamloot
Senior Vice President of Technical Operations
70
4 Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience
70
5 Dr. George Thornton Ph.D.
Senior Vice President of Technology
70
6 Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
70
7 Mr. R. Christopher Cook
Senior Vice President, Company Secretary & General Counsel
70
8 Mr. Eric J. Schoen
Chief Financial Officer
70

Cassava Sciences, Inc. Competitors